Unfortunately, a phase 3, randomized, double-blinded clinical trial failed to show a survival benefit of the EGFR deletion mutation vaccine rindopepimut (CDX-110) on newly diagnosed EGFRνIII positive glioma patients [60]. Here, EGFR is linked to glioma.